Sara Villar Fernández-rekin lankidetzan egindako argitalpenak (9)

2023

  1. Biallelic TET2 mutations confer sensitivity to 5′-azacitidine in acute myeloid leukemia

    JCI Insight, Vol. 8, Núm. 2

  2. Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia

    Blood Advances, Vol. 7, Núm. 1, pp. 167-173

  3. Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia

    Frontiers in Immunology, Vol. 14

  4. Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia

    British Journal of Haematology

2022

  1. Explainable artificial intelligence for precision medicine in acute myeloid leukemia

    Frontiers in Immunology, Vol. 13

  2. The transcriptomic landscape of elderly acute myeloid leukemia identifies B7H3 and BANP as a favorable signature in high-risk patients

    Frontiers in Oncology, Vol. 12

  3. Updates on the Management of Acute Myeloid Leukemia

    Cancers, Vol. 14, Núm. 19

2021

  1. Measurable residual disease in elderly acute myeloid leukemia: Results from the PETHEMA-FLUGAZA phase 3 clinical trial

    Blood Advances, Vol. 5, Núm. 3, pp. 760-770

2018

  1. Anti-PD1 associated fulminant myocarditis after a single pembrolizumab dose: The role of occult pre-existing autoimmunity

    Haematologica